Emmanuel Naveen Raj^1,#, Chia-Jung Li^1,2,3,4,5,#, Shih-Hsuan Cheng¹, Su-Boon Yong^6,7, Zhi-Hong Wen^3,8, An-Jen Chiang^1,9,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.079551 - 13 August 2026

Abstract Objectives: Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) necessitate the discovery of novel biomarkers for prognostic and therapeutic advancement. This study aims to evaluate the clinical significance of ubiquitin-conjugating enzyme E2C (UBE2C) and its association with the tumor microenvironment (TME) in CESC. Methods: We meticulously sourced CESC data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Gene Expression Omnibus (GEO), leveraging cutting-edge techniques including single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics. Through multifaceted data analysis, we endeavored to unravel the intricate role and potential value of UBE2C in… More > Graphic Abstract

Yiming Ma^1,2,#, Zhihan Zhang^1,2,#, Hongli Pan³, Hailin Jiang^1,2, Lili Guo^4,*, Fengjie Guo^1,2,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.079515 - 16 July 2026

Abstract Objectives: Lung adenocarcinoma (LUAD) has a poor prognosis, and effective metabolic biomarkers are still few. Glutamine metabolism is one of the central features of tumor metabolic reprogramming, but the cellular heterogeneity and clinical significance of glutamine metabolism in the LUAD tumor microenvironment (TME) remain unknown. The goal of this paper was to define glutamine metabolism on a single-cell basis and determine major regulators that have predictive value. Methods: A single-cell RNA sequencing dataset (GSE149655) was combined with The Cancer Genome Atlas Lung Adenocarcinoma (TCGA-LUAD) and Gene Expression Omnibus (GEO) datasets in order to evaluate the… More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.085235 - 21 May 2026

Abstract This article has no abstract. More >

Weixiang Song^1,#, Yanbo Zhang^2,#, Xubo Shen¹, Qin Yu¹, Yujin Liu¹, Yongchun Yu³, Rui Chen^1,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.078665 - 21 May 2026

Abstract Objective: Osimertinib can selectively inhibit both epidermal growth factor receptor (EGFR) sensitizing and T790M gatekeeper mutations, and has shown remarkable therapeutic effects in patients with lung adenocarcinoma. However, almost all patients inevitably develop drug resistance. Herein, we sought to clarify the roles of exosomal lncRNA H19 in modulating osimertinib resistance, focusing on the PI3K-PTEN-Akt signaling axis. Methods: Functional assays, including cell viability assay, colony formation, cell apoptosis and xenograft mouse, employed in evaluate the effects of exosomal lncRNA H19 on cell growth and apoptosis. RNA quantitation and western blot were adopted to demonstrate the regulatory roles of… More >

Thanh Hoa Vo^1,2, Edel McNeela^1,2, Orla O’Donnovan^1,2, Jai Prakash Mehta³, Van Hoa Nguyen⁴, Sweta Rani^1,2,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.075346 - 21 May 2026

Abstract Long non-coding RNAs (lncRNAs) have emerged as key regulators of drug resistance in human epidermal growth factor receptor 2 (HER2)-positive breast cancer, a subtype in which both intrinsic and acquired resistance to HER2-targeted therapies remain major clinical challenges. Although mechanistic studies have begun to reveal how lncRNAs modulate signaling pathways, interact with microRNAs, and influence the tumor microenvironment, dedicated investigations in HER2-positive disease are still limited. This review synthesizes current evidence across epigenetic, transcriptional, and post-transcriptional mechanisms of resistance, including competing endogenous RNA (ceRNA) networks, RNA-binding protein interactions, and exosome-mediated intercellular communication. Particular emphasis is… More >

Yan Zhu^1,#, Bin Guan^1,#, Wencai Guan¹, Jihong Zhang¹, Shiyu Wang¹, Jimin Shi¹, Wei Fan¹, Qi Lu^2,3, Lingyun Zhang^4,5,*, Guoxiong Xu^1,2,*

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.075241 - 22 April 2026

Abstract Background: Ovarian cancer poses the greatest threat to survival among gynecologic cancers in women. Long non-coding RNAs (lncRNAs) have emerged as critical regulators in oncogenesis. The current study aimed to elucidate the function and regulatory mechanism of lncRNA KRT7-AS in ovarian cancer. Methods: The clinical significance of KRT7-AS was evaluated through bioinformatics analysis of data from public repositories. KRT7-AS expression was examined by RT-qPCR and fluorescence in situ hybridization. The function analyses were conducted using assays for cell proliferation, migration, invasion, wound healing, and colony formation. Assessment of cell cycle and apoptosis was performed using flow… More >

Yiming Chen^1,2, Qiong Luo^1,*

Phyton-International Journal of Experimental Botany, Vol.95, No.3, 2026, DOI:10.32604/phyton.2026.077896 - 31 March 2026

Abstract Lycium ruthenicum Murray (black goji berry) is an economically important crop rich in anthocyanins, however, the post-transcriptional regulatory mechanisms underlying anthocyanin accumulation in its fruits are unknown. Here, we used whole-transcriptome sequencing to identify differentially expressed circRNAs and lncRNAs in black goji (BS4) and white goji (WS4). Furthermore, we analyzed the regulatory networks of the key ncRNAs and their target genes by combining targeted phytohormone metabolomics with molecular docking technology. We found that the circRNA plantcirc_001165 synergistically upregulated the flavonoid biosynthesis gene LrHCT with the lncRNA MSTRG.28703 to promote anthocyanin accumulation. However, MSTRG.28703 repressed LrZOX1 expression, leading More >

Kai Tang¹, Shengxing Lu¹, Cuie He², Ruozeng Rong^1,*

BIOCELL, Vol.50, No.3, 2026, DOI:10.32604/biocell.2026.072154 - 23 March 2026

Abstract Objectives: Prostate cancer (PCa) is a highly prevalent male malignancy with limited efficacy in advanced stages. Dysregulated modulation of necroptosis was reported to be tightly correlated with PCa initiation and progression. Herein, we aimed to identify necroptosis-associated long non-coding RNAs (lncRNAs) and delineate their functional roles in PCa through an integrated approach combining bioinformatic analyses and in vitro experimental validation. Methods: RNA sequencing data and corresponding clinical information of PCa were downloaded from The Cancer Genome Atlas (TCGA). Differentially expressed necroptosis-related genes (NRGs) and lncRNAs were screened, and necroptosis activity was assessed by single-sample gene set… More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2026.080056 - 24 February 2026

Abstract This article has no abstract. More >

Yimao Wu^1,2,#, Yitong Liu^2,#, Ruowei Sun^3,#, Yiyuan Zhang², Qian Zhang^4,*, Chen Li^5,*, Mengyao Li^1,6,*

Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2026.075012 - 24 February 2026

Abstract Tumor metabolic reprogramming is a core hallmark of cancer, characterized by pathways such as aerobic glycolysis, aberrant lipid metabolism, and glutaminolysis that support rapid proliferation and immunosuppressive microenvironments. Circular RNAs (circRNAs) are highly stable, evolutionarily conserved non-coding RNAs that have emerged as critical modulators of these metabolic shifts. This review aims to systematically elucidate the roles and mechanisms of circRNAs in reprogramming tumor metabolism, and to discuss their clinical potential as biomarkers and therapeutic targets. Through mechanisms including miRNA sponging, protein interactions, regulation of mitochondrial dynamics, and modulation of metabolic enzymes, circRNAs influence key metabolic… More >